WARNINGS O
In O
patients O
with O
hepatic B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
and O
ascites B-Not_AE_Candidate
, O
furosemide O
therapy O
is O
best O
initiated O
in O
the O
hospital O
. O

In O
hepatic B-Not_AE_Candidate
coma I-Not_AE_Candidate
and O
in O
states O
of O
electrolyte B-Not_AE_Candidate
depletion I-Not_AE_Candidate
, O
therapy O
should O
not O
be O
instituted O
until O
the O
basic O
condition O
is O
improved O
. O

Sudden O
alterations B-NonOSE_AE
of I-NonOSE_AE
fluid I-NonOSE_AE
and O
electrolyte O
balance I-NonOSE_AE
in O
patients O
with O
cirrhosis B-Not_AE_Candidate
may O
precipitate O
hepatic B-NonOSE_AE
coma I-NonOSE_AE
; O
therefore O
, O
strict O
observation O
is O
necessary O
during O
the O
period O
of O
diuresis B-NonOSE_AE
. O

Supplemental O
potassium O
chloride O
and O
, O
if O
required O
, O
an O
aldosterone O
antagonist O
are O
helpful O
in O
preventing O
hypokalemia B-NonOSE_AE
and O
metabolic B-NonOSE_AE
alkalosis I-NonOSE_AE
. O

If O
increasing O
azotemia B-NonOSE_AE
and O
oliguria B-NonOSE_AE
occur O
during O
treatment O
of O
severe O
progressive O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
furosemide O
should O
be O
discontinued O
. O

Cases O
of O
tinnitus B-OSE_Labeled_AE
and O
reversible O
or O
irreversible B-OSE_Labeled_AE
hearing I-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
and O
deafness B-OSE_Labeled_AE
have O
been O
reported O
. O

Reports O
usually O
indicate O
that O
furosemide O
ototoxicity B-OSE_Labeled_AE
is O
associated O
with O
rapid O
injection O
, O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
use O
of O
higher O
than O
recommended O
doses O
, O
hypoproteinemia B-Not_AE_Candidate
, O
or O
concomitant O
therapy O
with O
aminoglycoside O
antibiotics O
, O
ethacrynic O
acid O
, O
or O
other O
ototoxic B-NonOSE_AE
drugs I-NonOSE_AE
. O

If O
the O
physician O
elects O
to O
use O
high O
dose O
parenteral O
therapy O
, O
controlled O
intravenous O
infusion O
is O
advisable O
( O
for O
adults O
, O
an O
infusion O
rate O
not O
exceeding O
4 O
mg O
furosemide O
per O
minute O
has O
been O
used O
) O
. O

( O
See O
PRECAUTIONS O
: O
Drug O
Interactions O
) O

